[1. LI S., HONG M., TAN H., WANG N., FENG Y. Insights into the role and interdependence of oxidative stress in inflammation in liver diseases. Oxid Med Cell Longev. 2016; 2016:4234061.10.1155/2016/4234061]Search in Google Scholar
[2. ZHAN Y., AN W. Roles of liver innate immune cells in nonalcoholic fatty liver disease. World J Gastroenterol. 2010; 16(37):4652–4660.10.3748/wjg.v16.i37.4652295151520872965]Search in Google Scholar
[3. LIU Y., ZHONG G., TAN H., HAO F., HU J. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta analysis. Sci Rep. 2019; 9:11124.10.1038/s41598-019-47687-3666840031366982]Search in Google Scholar
[4. KUMAR A., SINGH AK., PANDA PK., NISCHAL N., SONEJA M. Non-alcoholic fatty liver disease diagnosis, grading and staging; a simplified tool for clinicians. JAM. 2017; 6(1):15–22.10.5958/2319-4324.2017.00003.7]Search in Google Scholar
[5. LUCI C., VIEIRA E., PERCHET T., GUAL P., GOLUB R. Natural killer cells and type 1 innate lymphoid cells are new actors in non-alcoholic fatty liver disease. Front Immunol. 2019; 10:1192.10.3389/fimmu.2019.01192654684831191550]Search in Google Scholar
[6. HAMMERICH L, TACKE F. Interleukins in chronic liver disease: lessons learned from experimental mouse models. Clin Exp Gastroenterol. 2014;7:297–306.]Search in Google Scholar
[7. HAMMERICH L., TACKE F. Interleukins in chronic liver disease: lessons learned from experimental mouse models. Clin Exp Gastroenterol. 2014; 7:297–306.10.2147/CEG.S43737]Search in Google Scholar
[8. ARRESE M., CABRERA D., KALERGIS AM., FELDSTEIN AE. Innate immunity and inflammation in NAFLD/NASH. Dig Dis Sci. 2016; 61(5):1294–1303.10.1007/s10620-016-4049-x494828626841783]Search in Google Scholar
[9. GILES DA., MORENO-FERNANDEZ ME., DIVANOVIC S. IL-17 axis driven inflammation in non-alcoholic fatty liver disease progression. Curr Drug Targets. 2015; 16(12):1315–1323.10.2174/1389450116666150531153627492985726028039]Search in Google Scholar
[10. DASARATHY S., DASARATHY S., KHIYAMI A., JOSEPH R., LOPEZ R., MCCULLOUGH AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009; 51(6):1061–1067.10.1016/j.jhep.2009.09.001613614819846234]Search in Google Scholar
[11. SHANNON A., ALKHOURI N., CARTER-KENT C., MONTI L., DEVITO R., LOPEZ R., et al. Ultrasonographic quantitative estimation of hepatic steatosis in children with NAFLD. J Pediatr Gastroenterol Nutr. 2011; 53(2):190–195.10.1097/MPG.0b013e31821b4b61314450521788761]Search in Google Scholar
[12. YOUNOSSI ZM., KOENIG AB., ABDELATIF D., FAZEL Y., HENRY L., WYMER M. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(1):73–84.10.1002/hep.28431]Search in Google Scholar
[13. DYSON JK., ANSTEE QM., MCPHERSON S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014; 5(3):211–218.10.1136/flgastro-2013-100403407866625018867]Search in Google Scholar
[14. JENNISON E., PATEL J., SCORLETTI E., BYRNE CD. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019; 95(1124):314–322.10.1136/postgradmedj-2018-13631631085617]Search in Google Scholar
[15. SANNA C., ROSSO C., MARIETTI M., BUGIANESI E. Non-alcoholic fatty liver disease and extra-hepatic cancers. Int J Mol Sci. 2016; 17(5):717.10.3390/ijms17050717488153927187365]Search in Google Scholar
[16. STOJSAVLJEVIC S., PALCIC MG., JUKIC LV., DUVNJAK LS, DUVNJAK M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014; 20(48):18070–18091.10.3748/wjg.v20.i48.18070427794825561778]Search in Google Scholar
[17. SUTTI S., ALBANO E. Adaptive immunity: an emerging player in the progression of NAFLD. Nat Rev Gastroenterol Hepatol. 2020; 17(2):81–92.10.1038/s41575-019-0210-2722295331605031]Search in Google Scholar
[18. BRAUNERSREUTHER V., VIVIANI GL., MACH F., MONTECUCCO F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol. 2012; 18(8):727–735.10.3748/wjg.v18.i8.727328613522371632]Search in Google Scholar
[19. KREMER M., THOMAS E., MILTON RJ., PERRY AW., VAN ROOIJEN N., WHEELER MD. Kupffer cell and interleukin-12 dependent loss of natural killer T cells in hepatosteatosis. Hepatology. 2010; 51(1):130–141.10.1002/hep.23292376196220034047]Search in Google Scholar
[20. AJMERA V., PERITO ER., BASS NM., TERRAULT NA., YATES KP., GILL R., et al. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology. 2017; 65(1):65–77.10.1002/hep.28776519193227532276]Search in Google Scholar
[21. TARANTINO G., CITRO V, CONFORTI P, BALSANO C, CAPONE D. Is there a link between basal metabolic rate, spleen volume and hepatic growth factor levels in patients with obesity-related NAFLD? JCM. 2019; 8:1510.10.3390/jcm8101510]Search in Google Scholar
[22. XIAO G., ZHU S., XIAO X., YAN L., YANG J., WU G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatol. 2017; 66:1486–501.10.1002/hep.2930228586172]Search in Google Scholar
[23. CLEVELAND E., BANDY A., VANWAGNER LB. Diagnostic challenges of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Clin Liver Dis (Hoboken). 2018/04/20 ed. 2018;11:98–104.10.1002/cld.716]Search in Google Scholar